Is there a preferred agent for VTE prophylaxis in trauma patients? Is there a superior dosing strategy for these high-risk patients?
The selection and dosing of pharmacologic VTE prophylaxis in trauma patients has a troubled, controversial past. The literature surrounding the topic is riddled with small, conflicting trials and methodological flaws.